Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach

Crystal A Gadegbeku, Debbie S Gipson, Lawrence B Holzman, Akinlolu O Ojo, Peter X K Song, Laura Barisoni, Matthew G Sampson, Jeffrey B Kopp, Kevin V Lemley, Peter J Nelson, Chrysta C Lienczewski, Sharon G Adler, Gerald B Appel, Daniel C Cattran, Michael J Choi, Gabriel Contreras, Katherine M Dell, Fernando C Fervenza, Keisha L Gibson, Larry A Greenbaum, Joel D Hernandez, Stephen M Hewitt, Sangeeta R Hingorani, Michelle Hladunewich, Marie C Hogan, Susan L Hogan, Frederick J Kaskel, John C Lieske, Kevin E C Meyers, Patrick H Nachman, Cynthia C Nast, Alicia M Neu, Heather N Reich, John R Sedor, Christine B Sethna, Howard Trachtman, Katherine R Tuttle, Olga Zhdanova, Gastòn E Zilleruelo, Matthias Kretzler, Crystal A Gadegbeku, Debbie S Gipson, Lawrence B Holzman, Akinlolu O Ojo, Peter X K Song, Laura Barisoni, Matthew G Sampson, Jeffrey B Kopp, Kevin V Lemley, Peter J Nelson, Chrysta C Lienczewski, Sharon G Adler, Gerald B Appel, Daniel C Cattran, Michael J Choi, Gabriel Contreras, Katherine M Dell, Fernando C Fervenza, Keisha L Gibson, Larry A Greenbaum, Joel D Hernandez, Stephen M Hewitt, Sangeeta R Hingorani, Michelle Hladunewich, Marie C Hogan, Susan L Hogan, Frederick J Kaskel, John C Lieske, Kevin E C Meyers, Patrick H Nachman, Cynthia C Nast, Alicia M Neu, Heather N Reich, John R Sedor, Christine B Sethna, Howard Trachtman, Katherine R Tuttle, Olga Zhdanova, Gastòn E Zilleruelo, Matthias Kretzler

Abstract

The Nephrotic Syndrome Study Network (NEPTUNE) is a North American multicenter collaborative consortium established to develop a translational research infrastructure for nephrotic syndrome. This includes a longitudinal observational cohort study, a pilot and ancillary study program, a training program, and a patient contact registry. NEPTUNE will enroll 450 adults and children with minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy for detailed clinical, histopathological, and molecular phenotyping at the time of clinically indicated renal biopsy. Initial visits will include an extensive clinical history, physical examination, collection of urine, blood and renal tissue samples, and assessments of quality of life and patient-reported outcomes. Follow-up history, physical measures, urine and blood samples, and questionnaires will be obtained every 4 months in the first year and biannually, thereafter. Molecular profiles and gene expression data will be linked to phenotypic, genetic, and digitalized histological data for comprehensive analyses using systems biology approaches. Analytical strategies were designed to transform descriptive information to mechanistic disease classification for nephrotic syndrome and to identify clinical, histological, and genomic disease predictors. Thus, understanding the complexity of the disease pathogenesis will guide further investigation for targeted therapeutic strategies.

Figures

Figure 1. NEPTUNE Cohort Study Design
Figure 1. NEPTUNE Cohort Study Design
Figure 2. Overview of Multilevel Data Integration…
Figure 2. Overview of Multilevel Data Integration in NEPTUNE
“The integrative analytical approach in NEPTUNE relies on obtaining comprehensive molecular and clinical information from each subject. For molecular analysis, the initial step is to generate large-scale datasets of genome-wide genetic variation and targeted gene sequencing, compartment specific gene expression data on renal biopsy tissue, leukocytes and urine, and proteomic/metabolomic data from both urine and blood samples. Each molecular dataset will be interrogated alone and in relationship with the others in order to understand multidimensional molecular interactions. In addition, the molecular data will be analyzed with the comprehensive clinical information to determine associations between molecular events and clinical outcomes. The overall goal is to develop a framework for studies to define the molecular heterogeneity of NS for disease stratification, biomarker identification and molecular target definition. (Figure modified from Keller et al).”

References

    1. Maisonneuve P, Agodoa L, Gellert R, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35:157–165.
    1. U S Renal Data System, USRDS. 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2011. 2011.
    1. Kretzler M, Cohen CD. Integrative biology of renal disease: toward a holistic understanding of the kidney's function and failure. Semin Nephrol. 2010;30:439–442.
    1. Hladunewich MA, Troyanov S, Calafati J, et al. The natural history of the non-nephrotic membranous nephropathy patient. Clinical journal of the American Society of Nephrology : CJASN. 2009;4:1417–1422.
    1. Schwartz MM, Evans J, Bain R, et al. Focal segmental glomerulosclerosis: prognostic implications of the cellular lesion. Journal of the American Society of Nephrology : JASN. 1999;10:1900–1907.
    1. Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics. 2009;124:747–757.
    1. Working Group of the International Ig ANN, the Renal Pathology S. Cattran DC, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney international. 2009;76:534–545.
    1. Barisoni L, Jennette JC, Colvin R, Sitaraman S, Bragat A, Castelli J, Boudes P. A novel quantitative method to evaluate GL-3 inclusions in renal peritubular capillaries by virtual microscopy in patients with Fabry's disease. Archives of pathology & laboratory medicine. in press.
    1. Sauer U, Heinemann M, Zamboni N. Genetics. Getting closer to the whole picture. Science. 2007;316:550–551.
    1. Keller BJ, Martini S, Sedor JR, et al. A systems view of genetics in chronic kidney disease. Kidney international. 2012;81:14–21.
    1. Velic A, Macek B, Wagner CA. Towards quantitative proteomics of organ substructures: implications for renal physiology. Sem Nephrol. 2010
    1. Perco P, Oberbauer R. Integrative analysis of ‘-omics’ data and histological scoring in renal disease and transplantation: renal histogenomics. Sem Nephrol. 2010
    1. Ju W, Brosius FC., 3rd Understanding Kidney Disease: Toward the Integration of Regulatory Networks Across Species. Sem Nephrol. 2010
    1. He JC, Chuang PY, Ma'ayan A, et al. Systems biology of kidney diseases. Kidney international. 2012;81:22–39.
    1. Diggle P, Heagerty P, Liang K-Y, Zeger SL. Analysis of longitudinal data. 2nd edn. New York: Oxford University Press; 2002.
    1. Dudoit SFJ, Speed TP. Comparison of discrimination methods for tumor classification based on microarray data. JASA. 2002;97:77–87.
    1. Ma S, Song X, Huang J. Regularized binormal ROC method in disease classification using microarray data. BMC bioinformatics. 2006;7:253.
    1. Zhou X, Obuchowski A, McClish DK. Statistical methods in diagnostic medicine. New York: Wiley; 2002.
    1. Pencina MJ, D'Agostino RB, Sr, D'Agostino RB, Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statistics in medicine. 2008;27:157–172. discussion 207-112.
    1. Dobbin KKSR. Sample size planning for developing classifiers using high-dimensional DNA microarray data. Biostatistics. 2007:101–117.
    1. Srivastava T, Simon SD, Alon US. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol. 1999;13:13–18.
    1. Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney international. 2004;66:571–579.
    1. Vats A, Nayak A, Ellis D, et al. Familial nephrotic syndrome: clinical spectrum and linkage to chromosome 19q13. Kidney international. 2000;57:875–881.
    1. Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clinical journal of the American Society of Nephrology : CJASN. 2007;2:529–542.
    1. Albaqumi M, Barisoni L. Current views on collapsing glomerulopathy. Journal of the American Society of Nephrology : JASN. 2008;19:1276–1281.
    1. Winn MP, Conlon PJ, Lynn KL, et al. Clinical and genetic heterogeneity in familial focal segmental glomerulosclerosis. International Collaborative Group for the Study of Familial Focal Segmental Glomerulosclerosis. Kidney international. 1999;55:1241–1246.
    1. Hinkes B, Wiggins RC, Gbadegesin R, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet. 2006;38:1397–1405.
    1. Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. Journal of the American Society of Nephrology : JASN. 2007;18:2773–2780.
    1. McTaggart SJ, Algar E, Chow CW, et al. Clinical spectrum of Denys-Drash and Frasier syndrome. Pediatr Nephrol. 2001;16:335–339.
    1. Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney international. 2011;80:868–878.
    1. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40:1175–1184.
    1. Tzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128:345–350.
    1. Genovese G, Tonna SJ, Knob AU, et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney international. 2010;78:698–704.
    1. Cameron JS. Membranous nephropathy and its treatment. Nephrol Dial Transplant. 1992;7(Suppl 1):72–79.
    1. Haas M, Meehan SM, Karrison TG, et al. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. Am J Kidney Dis. 1997;30:621–631.
    1. Cattran DC, Pei Y, Greenwood CM, et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney international. 1997;51:901–907.
    1. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney international. 1992;42:960–966.
    1. Perna A, Schieppati A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004;44:385–401.
    1. Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. The New England journal of medicine. 2011;364:616–626.
    1. Ronco P, Debiec H. Advances in membranous nephropathy: success stories of a long journey. Clin Exp Pharmacol Physiol. 2011;38:410–416.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa